Efalizumab
- Generic Name
- Efalizumab
- Drug Type
- Biotech
- CAS Number
- 214745-43-4
- Unique Ingredient Identifier
- XX2MN88N5D
- Background
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).
- Indication
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Moderate to Severe Chronic Plaque Psoriasis
Efalizumab to Treat Uveitis
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 6
- Registration Number
- NCT00280826
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Islet Transplantation Using Abatacept
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT00276250
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
CLEAR Study: Clinical Experience Acquired With Raptiva Study
- Conditions
- Moderate to Severe Psoriasis
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 793
- Registration Number
- NCT00256139
- Locations
- π¨π
Serono International SA, Geneva, Switzerland
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1266
- Registration Number
- NCT00249808
- Locations
- π¬π§
Medical Information, Feltham, United Kingdom
Efalizumab for Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 10
- Registration Number
- NCT00226057
Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 96
- Registration Number
- NCT00184366
- Locations
- π³π΄
Dep of dermatology, St Olavs Hospital, Trondheim, Norway
Efalizumab for Eczema
- Conditions
- Dermatitis, Atopic
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2008-08-07
- Target Recruit Count
- 10
- Registration Number
- NCT00146003
- Locations
- πΊπΈ
UMDNJ Psoriasis Center of Excellence, New Brunswick, New Jersey, United States
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 5
- Registration Number
- NCT00134134
- Locations
- πΊπΈ
New York University School of Medicine, Dept of Dermatology, New York, New York, United States
Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus
- Conditions
- Lichen Planus, Oral
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT00133107
- Locations
- πΊπΈ
Washington University, St. Louis, Missouri, United States
Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2005-06-21
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 31
- Registration Number
- NCT00115076
- Locations
- πΊπΈ
The Rockefeller University, New York, New York, United States
πΊπΈRockefeller University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.